Ozempic, Wegovy: Stopping Use Causes Fast Weight Regain
A new BMJ study reveals alarming weight regain after stopping drugs like Ozempic. Experts warn against treating them as short-term trends. Learn the facts and risks.
Category : Search result: Ozempic generic
Stopping Weight-Loss Jabs Leads to Rapid Weight Regain: BMJ
A new BMJ study reveals that discontinuing weight-loss drugs like Ozempic and Mounjaro leads to regaining all lost weight within 1.5 years. Experts advise on long-term management strategies.
Trump on weight-loss drugs: 'No, I have not. I probably should.'
In a NYT interview, Donald Trump revealed he hasn't used GLP-1 drugs like Ozempic, sparking debate on obesity, healthcare costs, and his administration's drug price policies. Read the full story.
Natco Pharma Sues to Revoke Novo Nordisk's Semaglutide Patent
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Oatzempic: Viral Oat Drink Compared to Weight Loss Injections
Oatzempic, a viral oat-based drink, is being hailed as a natural alternative to weight loss injections. Discover its recipe, benefits, and the expert warnings you need to know before trying it.
Oatzempic Trend: Does the Viral Oat Drink Work Like Ozempic?
The 'Oatzempic' drink is trending on TikTok for weight loss. Experts reveal if this oat-based concoction can truly mimic the effects of the prescription drug Ozempic or if it's just another fad.
Generic Drugs as Good as Brands, Cost Far Less: Study
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
India's 2025 Health Shift: Prevention, Generics & Digital Tools
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
Bariatric Surgery Outperforms GLP-1 Drugs Like Ozempic
New research reveals bariatric surgery delivers five times more weight loss than GLP-1 drugs like Ozempic over two years. Discover the real-world data and what it means for obesity treatment.
2025: The Year Weight-Loss Drugs Redefined Health in India
Explore how 2025's weight-loss drug boom in India shifted focus from fitness to thinness, raising concerns about medicalisation, side effects, and societal pressure. Read the full analysis.
2025 Weight Loss Trend: Experts Stress Lifestyle Over Injections
As GLP-1 drugs like Ozempic launched in India, experts warn they are not a magic fix. Sustainable metabolic health requires diet, exercise, and stress management. Learn why.
India's Weight-Loss Drug Market to Grow 10x by 2030
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Ozempic, Wegovy Reduce Food Spending, New Study Finds
New research reveals GLP-1 weight-loss drugs like Ozempic significantly cut grocery and restaurant spending. Discover the impact on food habits in India and globally.
Zota Health Raises ₹350 Crore, Signs Dhoni & Shetty
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
Why Stopping Weight-Loss Jabs Feels Like 'Jumping Off a Cliff'
Women share harrowing experiences of stopping anti-obesity drugs like Wegovy. Experts warn 60-80% weight returns without a plan. Learn about the side effects and new drugs in India.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Ozempic Face: Skincare Trend from Weight Loss Drugs
Rapid weight loss from GLP-1 drugs like Ozempic is causing 'Ozempic face'—facial thinning & sagging. Learn about prevention, treatments, and the 50% rise in cosmetic procedures. #Beauty #Skincare
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Jan Aushadhi Kendra rules changed: 500-meter gap enforced
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Ram Kapoor reveals secret behind his 50kg weight loss
Actor Ram Kapoor opens up about his 55kg weight loss journey, battling type-2 diabetes, and his mindset shift. Discover his inspiring health transformation story.
Psyllium Husk: India's Natural Answer to Weight Loss Drugs
Psyllium husk, dubbed 'Desi Ozempic,' is trending as a natural appetite suppressant. Discover how this common fiber compares to prescription drugs and its role in weight management.
Karnataka to appeal HC order on Jan Aushadi Kendras closure
Karnataka Health Minister Dinesh Gundu Rao announces state will appeal HC order quashing closure of Jan Aushadi Kendras in govt hospitals. Read the full story.
Page 1 of 3